Synapse - Joachim Yahalom

Search Within

Joachim Yahalom

Results (625)

Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study

Meeting Abstract

Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
Blood (2021)

Fulltext@MSK | Save

Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center

Meeting Abstract

Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
Blood (2021)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save

Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy

Meeting Abstract

Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
Blood (2021)

Fulltext@MSK | Save

Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience

Meeting Abstract

Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
Blood (2021)

Fulltext@MSK | Save

Radiation therapy for patients with diffuse large B cell Richter's syndrome of CLL

Meeting Abstract

Sacchi De Camargo Correia, G.; Imber, B. S.; Hajj, C.; Thompson, M. C.; Mato, A. R.; Yahalom, J.; Roeker, L. E.
Blood (2021)

Fulltext@MSK | Save

Prediction of response to very low dose radiotherapy (4 Gy) in mature B-cell lymphomas using metabolic tumor volume

Meeting Abstract

Wijetunga, N. A.; Imber, B. S.; Lee, J.; Hajj, C.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2021)

Fulltext@MSK | Save

Predictors of response to very low dose radiotherapy (4Gy) for indolent B-cell lymphomas: Is 4Gy also suitable for potentially curable patients?

Meeting Abstract

Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Chelius, M.; Hajj, C.; Wijetunga, N. A.; Yang, J. C.; Casey, D. L.; Shepherd, A. F.; more...
International Journal of Radiation Oncology, Biology, Physics (2021)

Fulltext@MSK | Save

A proof-of-principle study of split-course bridging radiotherapy prior to commercial CD19 CAR T-cell therapies for patients with relapsed or refractory B-cell lymphomas

Meeting Abstract

Imber, B. S.; Palomba, M. L.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2021)

Fulltext@MSK | Save

"Big Boom" radiation treatment (RT) of 4 Gy single fraction: Is it an acceptable alternative to "Boom Boom" radiation treatment 2 Gyx2 fractions for non-Hodgkin lymphomas (NHL)?

Meeting Abstract

Hajj, C.; Lee, J.; Fregonese, B.; Imber, B. S.; Wijetunga, N. A.; Yang, J. C.; Casey, D. L.; Yahalom, J.
International Journal of Radiation Oncology, Biology, Physics (2021)

Fulltext@MSK | Save